Introduction
Approximately 16% of yearly cancer diagnoses worldwide are attributable to an infectious agent (de Martel et al., 2012) . The fraction of cancers linked to infection varies greatly by geographical location and socioeconomic factors: while only 7.4% of cancer diagnoses are the result of infection in developed countries, up to 22.9% of cancers in developing parts of the world arise due to infection. In Sub-Saharan Africa, a striking one-third of cancer diagnoses are the result of infection (de Martel et al., 2012) ; the majority of these cancers are the result of infection with an oncovirus. Thus, oncovirus-induced cancers are an important global concern.
Oncoviruses contribute to carcinogenesis by altering the function of cellular targets that play pivotal roles in the development of cancer. Over the past few decades, many of the cellular mechanisms by which oncoviruses induce malignant transformation have been elucidated. One of the best-documented cases of oncogenic viruses disrupting normal cellular functions involves the tumor suppressor protein, p53. Several oncogenic viral proteins-such as the E6 oncoprotein of high-risk human papillomavirus (HPV) types and the HBx oncoprotein of hepatitis B virus (HBV)-have inhibitory effects on the pro-apoptotic ability of p53. The high-risk HPVs have additional cellular targets: the E6 oncoprotein increases telomerase activity and the E7 oncoprotein degrades the retinoblastoma tumor suppressor protein (Scheffner et al., 1993; Boyer et al., 1996; Klingelhutz et al., 1996) .
There is strong evidence that activation of the hypoxia-inducible factor 1 (HIF-1) transcription factor is a common pathway affected by human oncogenic viruses. HIF proteins are major components of the innate hypoxic stress response in non-cancerous cells, acting as transcription factors for a multitude of genes required for adaptation under low oxygen conditions (Wang et al., 1995a) . Three HIF isoforms have been identified (i.e., HIF-1, HIF-2 and HIF-3), however research to date has focused primarily on HIF-1. As such, this review will focus on HIF-1, but HIF-2 and HIF-3 could be assessed in future studies of viral carcinogenesis.
Transcriptionally active HIF-1 is a heterodimer made up of α-and β-subunits (the β subunit is also known as aryl hydrocarbon receptor nuclear translocator (ARNT), which also dimerizes with several other transcription factor subunits). The dimer is a member of the basic helix loop helix-PER-ARNT-SIM (bHLH-PAS) family of transcription factors that play a role in cancer development (Bersten et al., 2013) . In normal, non-hypoxic cells, HIF-1α is continually synthesized and degraded, while HIF-1β is constitutively expressed to levels that remain relatively constant within the nucleus (Fig. 1A ). HIF-1 activity is largely dependent on the regulation of its α subunit at several levels including transcription, translation, ubiquitin-mediated protein breakdown, nuclear translocation, and association with transcriptional co-activators. HIF-1α mRNA is ubiquitously expressed and its levels are similar for most cell types studied between hypoxic and normoxic conditions (Wenger et al., 1997) . However, some cell types, such as hepatocellular carcinoma (HCC) Hep3B cells, exhibit an increase in HIF-1α transcription under hypoxic conditions (Wang et al., 1995a) . In vivo investigations initially uncovered the potential for environmental hypoxia inducing HIF-1α transcription (Wiener et al., 1996) , but Fig. 1 . Regulation of HIF-1 protein levels. The level of HIF-1 in a given cell is subject to its oxygen-independent synthesis (A) and oxygen-dependent degradation (B). (A) The synthesis of HIF-1α is augmented in an oxygen-independent manner by transcription factors acting on its upstream regulatory region (URR) and the PI3K/Akt and ERK/MAPK pathways acting on its translation. When a growth factor binds to its respective tyrosine kinase receptor, PI3K (in the PI3K pathway) or RAS (in the ERK/MAPK pathway) is activated. In the PI3K pathway, PI3K then activates Akt and subsequently mTOR. In the ERK/MAPK pathway, RAS activates RAF, which activates MEK and subsequently ERK. ERK activates MNK that, together with mTOR, deactivates the 4E-BP, which allows for the formation of the eIF-4E complex. Along with p70S6K1, that is also activated by ERK, eIF-4E enhances the translation of HIF-1α mRNA. (B) When oxygen is present, PHDs are active and hydroxylate HIF-1α at Pro-402 and/or Pro-564. HIF-1α-OH becomes ubiquitinylated by VHL and subsequently broken down by the 26S proteasome. Conversely, under hypoxic conditions, PHDs cannot hydroxylate HIF-1α and it will accumulate in the cytoplasm before translocating to the nucleus to complex with HIF-1β and p300/CBP to enhance target gene expression. A rectangular border represents nucleic acids and circles are proteins. Black and white backgrounds represent specific HIF-1 and effector cellular components, respectively. The dotted line represents the nuclear membrane. Refer to abbreviation list for full names.
conflicting studies found no such effect (Wenger et al., 1996; Stroka et al., 2001 ). More recent work has supported the notion that hypoxia can influence HIF-1α transcription through intermediate pathways (Sperandio et al., 2009; BelAiba et al., 2007) . Alternatively, analysis of the promoter and 5 0 -UTR of the HIF-1α gene revealed putative binding sites of several transcription factors in this region including specificity protein (SP-1), activator protein (AP-1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and HIF-1 itself (Minet et al., 1999) . Recent studies found that enhancing NF-κB and signal transducer and activator of transcription 3 (STAT-3) increase the transcription of HIF-1α (van Uden et al., 2008; Rius et al., 2008; Niu et al., 2008) .
While HIF-1α transcription is continual, several growth factors and their associated pathways play a role in enhancing HIF-1α signaling in an oxygen-independent manner by augmenting the translation of HIF-1α mRNA. In the phosphatidylinositol-3-kinase (PI3K) pathway, binding of a growth factor (e.g., insulin-like growth factor 1) to its cognate tyrosine kinase receptor (RTK) results in phosphorylation of PI3K, which in turn, activates the serine/threonine kinase, Akt (an action that can be inhibited by the tumor suppressor, PTEN), and subsequently phosphorylates mammalian target of rapamycin (mTOR) (Semenza, 2003) . Additionally, growth factors can act on the mitogen-activated protein kinase (MAPK) pathway such that MAPK kinase (MEK) is activated by RAF and goes on to phosphorylate MAPK (ERK). Activated ERK is then capable of phosphorylating p70S6K1, which is required for translation of HIF-1α mRNA. In addition to activation of p70S6K1, ERK also activates MAPK-interacting protein (MNK) that functions to activate the translation initiator, elF-4E together with mTOR by inhibiting the 4E binding protein (4E-BP) (Agani and Jiang, 2013) . In this fashion, the PI3K and MAPK pathways collectively function to initiate HIF-1α protein synthesis in an oxygen-independent manner (Fig. 1A) .
The majority of work surrounding HIF-1 regulation has been on its constitutive normoxic protein breakdown. HIF-1α degradation is initiated by hydroxylation at one of its proline residues (Pro-402 and/or Pro-564) by prolyl hydroxylases (PHD-1, PHD-2, and PHD-3) that use molecular oxygen as a co-substrate (Bruick and McKnight, 2001; Semenza, 2001) . Upon hydroxylation, HIF-1α-OH becomes ubiquitinylated by the von Hippel Lindau E3 ubiquitin ligase protein (VHL), and subsequent proteasomal breakdown occurs. When there is a lack of oxygen, PHDs cannot function, resulting in stabilization of HIF-1α in the cytoplasm. Once HIF-1α accumulates in the cytoplasm it may translocate to the nucleus by way of α/β importins that requires a nuclear localization signal (NLS) sequence in HIF-1α's C-terminus transactivation domain (Depping et al., 2008) . Once in the nucleus, HIF-1α may dimerize with HIF-1β followed by HIF-1 complexing with the transcriptional co-activators p300/CBP. Several studies have found that phosphorylation of HIF-1α by way of the MAPK pathways enhance stability and may also be required for transactivation (Richard et al., 1999; Suzuki et al., 2001; Liu et al., 2003) in addition to other posttranslational modifications that alter HIF-1 function including acetylation (Lim et al., 2010) and small ubiquitin-like modifier (SUMO)ylation (Cheng et al., 2007) . Furthermore, complex formation is inhibited under hypoxic conditions by the hydroxylase, factor inhibiting HIF-1 (FIH-1). Similar to the PHDs, FIH-1 hydroxylates the transactivation domain of HIF-1α at Asn-803, which inhibits the binding of the heterodimer HIF-1 to its transcriptional coactivator p300 (Lando et al., 2002) . If each of these HIF-1-regulatory checkpoints are overcome in a given cell, activated HIF-1 binds to hypoxia response elements (HREs) in target gene promoters, transcriptionally activating a multitude of genes with specific roles in the hypoxic response (Fig. 1B) . Soon after the seminal discovery of HIF-1 by Semenza and colleagues in the early 1990s, it was found that its overexpression was common in a variety of cancers (Zhong et al., 1999; Krieg et al., 2000) . Moreover, increased HIF-1 has been associated with an unfavorable prognosis in most cancers, as it activates genes that play a role in promoting cancer metabolism, angiogenesis, invasion, and metastasis (Semenza, 2003 (Semenza, , 2010 (Semenza, , 2012 . Originally, this increase of HIF-1α in cancers was primarily attributed to stabilization by environmental hypoxia or genetic mutations (e.g., to VHL) in the pathways leading to the destruction of HIF-1α (Semenza, 2003) . However, it has now become clear that most, if not all, human oncogenic viruses directly enhance HIF-1, through various mechanisms affecting its activity. Thus, HIF-1 represents a common pathway affected by these genetically unrelated viruses.
In this review, we will outline the current understanding of the mechanisms by which oncogenic viruses promote HIF-1 activity, provide evidence for HIF-1's activation by oncoviruses in the upregulation of key downstream target genes involved in cancer progression, and highlight the activation of this pathway as a unifying event in viral-induced malignant transformation.
Oncogenic viruses enhance HIF-1α levels by modulating its transcription, translation, or stabilization
The inhibition of HIF-1α's transcriptional activity in noncancerous, normoxic cells, involves several processes-obstruction of any one of the sequential steps in HIF-1α destruction can lead to incomplete HIF-1α breakdown and subsequent activation of downstream genes. Furthermore, it appears as though an increase in HIF-1α mRNA translation via the PI3K/Akt/mTOR or MAPK signaling pathways can also lead to an increase in activation of target genes, such that the rate of proteasomal breakdown by the oxygen-dependent pathway of HIF-1α is insufficient to inhibit its transcriptional activity (Jiang et al., 2001; Laughner et al., 2001) . It is obvious that there exist multiple ways by which HIF-1 activity can be increased; each one of these pathways can potentially be targeted by oncogenic viruses for production of gene products conducive to cancer cell growth and spread (Tables 1 and 2 and Fig. 2 ). Whatever path may be taken, it is clear that six of the seven known oncogenic viruses have a component in their infectious arsenal that results in HIF-1 activity.
The human papillomaviruses
Human papillomaviruses (HPVs) were first described in the mid-1980s as a causative agent of cervical cancer (zur Hausen, 2002) , which could be either malignant (high-risk types) or benign (low-risk types). Several putative cellular targets of the two HPV oncogenes (E6 and E7) have been characterized, including p53, pRb (reviewed in Wise-Draper and Wells, 2007) , and more recently, HIF-1. The first evidence of HPV inducing HIF-1 activity came from in vivo studies of K14-HPV16 transgenic mice which harbor the entire early region of HPV16 under the control of the basal keratin 14 promoter. The authors reported an upregulation of HIF-1α and its target mRNAs during epidermal carcinogenesis (Elson et al., 2000) . The use of an in vivo model provided a context reminiscent of HPV infection where early genes are expressed in basal keratinocytes. However, in this particular study, quantification of viral gene expression and protein levels were not assessed for their correlation with the HIF-1 pathway. The authors continued these in vivo studies further characterizing the role of HIF-1 in cervical carcinogenesis (Lu et al., 2007) . Along with these in vivo assessments of the role of HIF-1 in HPV16 carcinogenesis, both the E6 and E7 oncogenes of high risk HPVs have been scrutinized for their ability to induce HIF-1 transcriptional activity.
The E6 oncogene has many well-studied cellular functions, including the proteasomal breakdown of p53 via the E3 ubiquitin ligase, E6-Associated Protein (E6-AP). The p53 tumor suppressor protein binds to and induces HIF-1α degradation thus the presence of E6 induces an increase in HIF-1α under hypoxic conditions (Ravi et al., 2000) . In their study, Ravi and colleagues confirmed that transfection of PA-1 ovarian teratocarcinoma cells with the high-risk HPV E6 oncogene boosts HIF-1α stability under hypoxic (1% O 2 ) culture conditions. While this study shows that E6-mediated p53 breakdown enhances HIF-1α, it is not clear whether or not this is reminiscent of an HPV infection as only E6 was introduced and levels of it's DNA copy number, mRNA and protein expression were not assessed. Although E6 was introduced into atypical host cells, the study set the stage for the investigation of HPV and HIF-1α in normal keratinocytes. The cell cycle progression-altering E7 oncogene of both highrisk (type 16, 18, 31) and low-risk (type 11) HPV increases HIF-1 activity in the presence of several histone deacetylases (HDACs) by binding to HIF-1α directly (Bodily et al., 2011) . The binding of E7 to HIF-1α was directly inhibited through deletion of the N-terminus pRb binding domain of E7. Many HDACs (including HDAC1, 4, and 7) enhance HIF-1 activity on their own (Kato et al., 2004; Qian et al., 2006; Yoo et al., 2006) , however the authors hypothesized that binding of HPV E7 to HIF-1α allows for the displacement of these HDAC's from HIF-1α, permitting formation of the HIF-1 transcription complex, leading to downstream activation of target genes. Previously, under conditions mimicking hypoxia, cells treated with the hypoxic mimetic, deferoxamine, plus high-risk HPV E7 or E6 exhibited higher protein levels of HIF-1α in comparison to non-transduced keratinocytes under the same conditions (Nakamura et al., 2009 ). The authors also looked at whole genome transfection of high risk (HPV31) and low risk (HPV11) viruses and found that HIF-1α protein levels were enhanced under hypoxic conditions. However, a full evaluation of viral mRNA and protein expression was not included. Thus, the magnitude of viral gene expression required for an observed increase in HIF-1α protein under these conditions by HPV is not conclusive. These findings held true for HPV16 E6 and E7 under normoxic conditions when transfected into HeLa (HPV18 þ) and C33A (HPV-) cervical cancer cell lines (Tang et al., 2007) . Future studies regarding the effect of HPV on the HIF-1 pathway are warranted in order to establish a quantifiable relationship between HPV expression and HIF-1 activity.
The hepatitis viruses
Infection with either hepatitis B (HBV) or C (HCV) induces severe liver cirrhosis and inflammation as seen in more than 80% of HCC patients (El-Serag, 2012) . Like the papillomaviruses, these two hepatitis viruses have carcinogenic properties that act on key cellular targets involved in apoptosis and promotion of the cell cycle during cancer progression (reviewed in: McGivern and Lemon, 2011; Fallot et al., 2012; Arzumanyan et al., 2013) . Both hepatitis viruses have also been studied for their effect on the HIF-1 pathway and its role in HCC progression. As stated previously, HIF-1 activity can be induced through disruption to its oxygendependent degradation, as well as by the oxygen-independent increase in growth factor signaling. The latter mechanism appears to occur in HBV-induced HCCs.
The major factor in the development of HCC induced by HBV is the HBx gene (Kim et al., 1991; Benn and Schneider, 1995; Fallot et al., 2012) . In addition to inflicting genetic instability and disrupting normal cell cycle control, the HBx protein (expressed by inducible Chang liver cells) independently increases the translation of HIF-1α mRNA leading to an increase in its transcriptional activity on target genes (Yoo et al., 2003) . This HIF-1α activation by HBx occurs via increased signaling of the MAPK pathway. Although the study provided a qualitative assessment of HBx protein by Table 2 Mechanisms of oncoviral induced HIF-1α enhancement (by level of HIF-1α regulation). Abbreviations: See text for full names of abbreviated viruses, viral proteins, and cellular targets.
Level of HIF-1α regulation
western blot, quantification was not performed. Measurement of induced HBx mRNA expression was also not reported. In addition to enhancing HIF-1α synthesis, its stabilization was also increased in HBx transfected liver and non-liver cells, by introducing terminal truncations to HBx to determine the specific binding region. This stabilization was accomplished solely by the C-terminus of HBx directly binding to the C-terminus to HIF-1α, potentially interfering with its association with PHDs or VHL (Yoo et al., 2004) . A concurrent, but separate study found direct binding between full length HBx and HIF-1α leading to stabilization of HIF-1α by inhibiting its interaction with VHL (Moon et al., 2004) . HBx can also indirectly cause a rise in HIF-1 via a signaling pathway containing the growth factor receptor, human epidermal growth factor receptor-2 (HER2, also known as ErbB2). Retroviral transduction of the HepG2 cell line with HBx leads to a transcriptional upregulation of ERBB2, and corresponding increase in its protein level (Liu et al., 2009) . Enhanced ERBB2 signaling then leads to higher HIF-1α levels through enhanced protein synthesis via the PI3K/Akt pathway (Laughner et al., 2001) . Increased Akt phosphorylation has been reported in HBx transduced HepG2 cells, potentially leading to downstream enhancement of HIF-1α synthesis, although in this paper, the authors did not report data on HIF-1α activity (Liu et al., 2009) . Collectively, these studies imply that the HBx protein increases HIF-1α activity through both inhibition of its oxygen-dependent degradation pathway, as well as through amplification of its synthesis through the MAPK pathway. Lastly, HBx has also been implicated in the upregulation of HIF-1 signaling by inducing the transcription of HDAC1 and metastasis-associated protein 1 (MTA1) leading to an increase in protein levels in vitro and in vivo (liver tissue of HBx-transgenic mice), which stabilizes HIF-1 under hypoxic conditions by inhibiting its association with PHDs and VHL (Yoo et al., 2008) . While these results at first glance appear to be in conflict with those involving HPV E7 and HDACs, it is possible that enhancement of HDAC1 transcription by HBx inhibits HIF-1α degradation, while binding of HPV E7 to HDACs augments its ability to form transcriptional complexes-this remains to be confirmed experimentally. Thus, the key oncogenic protein of HBV has acquired several mechanisms leading to upregulation of HIF-1α, which likely accounts for its significant association with the development and progression of HCCs.
Hepatitis C virus has also independently acquired its own mechanisms to increase HIF-1α. The first evidence of HIF-1α modulation by HCV came in 2007 when Nasimuzzaman and colleagues showed that HCV's non-structural proteins were capable of inducing HIF-1α protein levels, even under normoxic conditions (Nasimuzzaman et al., 2007) . Mechanistically, HCV infection induces oxidative stress, which in turn, activates several kinase pathways (Wang et al., 1998) , including the PI3K and MEK pathways that lead to increased HIF-1α synthesis (Tardif et al., 2005; Nasimuzzaman et al., 2007) . Treatment of HCV-infected HCC Huh-7 cells with MEK and PI3K inhibitors was sufficient to completely block the induction of HIF-1α. Although the authors used a liver-derived cell line, it would have been interesting to observe the effect of HCV-infection on normal hepatocytes, since HCC Huh-7 cells may already have altered pathways connected to HIF-1. In addition to the non-structural proteins, the HCV Core protein can independently induce HIF-1α and promote HCC (Ray et al., 1997; Moriya et al., 1998) . Under hypoxic conditions, stable transfection with the HCV Core protein (but not the non-structural protein NS5A or an empty vector) augmented HIF-1α by transcriptionally upregulating HIF-1α mRNA via activation of the NF-kB signaling pathway through an undetermined mechanism (Abe et al., 2012) . However, these results were found in HAK-1A hepatoma cells already containing HCV, so it is unclear how relevant this overexpression of Core is in relation to a natural HCV infection.
The oncogenic herpes viruses
Of the nine distinct human herpes virus (HHV) types known to cause disease, only the γ-herpes viruses-HHV-4 (Epstein-Barr virus or EBV) and HHV-8 (Kaposi's sarcoma-associated herpes virus or KSHV)-are oncogenic, and both are frequently found to cause cancers in immunocompromised individuals (Ramos da Silva and Elgui de Oliveira, 2011). EBV infections promote several cancers, including Burkitt's lymphoma, Hodgkin's disease, nonHodgkin's lymphoma, and nasopharyngeal carcinoma (Thompson and Kurzrock, 2004) . KSHV is a causative agent of Kaposi's sarcoma and primary effusion lymphoma-two cancers that are associated with HIV infection (Wen and Damania, 2010) . Each of these two oncogenic herpes viruses are also capable of increasing HIF-1α levels.
EBV primarily infects B cells of the immune system and can transform them to latently infected lymphoblastoid cell lines (LCL) in vitro. This occurs upon expression of a distinct repertoire of latent viral proteins known as the EBV nuclear antigens (EBNAs) and latent membrane proteins (LMPs) (Young and Rickinson, 2004; Kalla and Hammerschmidt, 2012 ). EBV's contribution to HIF-1 activity was first noted when LCLs of Type II and Type III latency expressing LMP-1 showed increased HIF-1α protein levels over HeLa control cells under normoxic conditions . Furthermore, stable or transient transfection of the nasopharyngeal carcinoma cell line Ad-AH with LMP-1 lead to a significant increase in HIF-1α protein levels as well as nuclear translocation and transcriptional activity as measured by a luciferase assay of the VEGF promoter containing an HRE. The underlying mechanism of LMP-1-induced HIF-1α protein level increase was determined to be solely due to an increase in its mRNA translation, rather than transcription, by activation of the p42/p44 MAPK pathway, but not of the p38 MAPK pathway . While the classical MEK/MAPK pathway is typically associated with promoting cell division and proliferation in response to growth factor stimulation, the p38/MAPK pathway is known, along with the JNK/MAPK pathway, to respond to inflammatory stresses and elicit apoptosis and cell cycle arrest in a variety of cell types (for review of mammalian MAPK pathways, see Qi and Elion, 2005) . In LMP-1-transfected Ad-AH cells, HIF-1α accumulation occurs via LMP-1's effect on increasing production of reactive oxygen species (ROS), particularly H 2 O 2 . This oxidative stress activates MAPK signaling (Chandel et al., 2000; Son et al., 2011) . Increased signaling along the p42/p44 MAPK pathways upon EBV LMP-1 transfection leading to HIF-1 activation could be the result of a direct LMP-1-induced increase in H 2 O 2 levels. In addition to enhancing the synthesis of HIF-1α, the same group later found that LMP-1 also functions to inhibit the degradation of HIF-1α by increasing the level of Siah-1 protein, a key E3 ubiquitin ligase that can induce the degradation of the PHDs required for HIF-1α breakdown (Kondo et al., 2006) . LMP-1 activation of Siah-1 was regulated at the protein level through inhibiting its breakdown. However, the precise mechanism of inhibiting Siah-1 breakdown by LMP-1 was not determined. This is the first evidence of an oncogenic viral protein interfering with the oxygen-dependent degradation of HIF-1α by inhibiting PHD activity, and provides a novel mechanism for HIF-1 activation to be explored in other cancers, particularly those of exogenous origin.
Several nuclear antigen proteins of EBV also function to increase HIF-1α. EBNA-1 enhances the transcriptional activity of activator protein 1 (AP-1), a transcription factor that targets the HIF-1α gene. Evidently, stable transfection of EBNA-1 into Ad-AH cells acts to initiate the transcription of HIF-1α (O'Neil et al., 2008) . However, whether the enhanced transcription of HIF-1α was mediated solely by the AP-1 transcription factor was not determined. Two other nuclear antigen proteins act to interfere with the degradation pathway of HIF-1α. As described previously, the oxygen-dependent degradation of HIF-1α requires the activity of PHD-1, PHD-2, and PHD-3 to hydroxylate HIF-1α, which is then ubiquitinylated by VHL and degraded by the 26S proteasome. Recent work illustrates that infection of full length EBV increases HIF-1α protein levels and translocation to the nucleus in comparison to normal cytokine-induced proliferating B cells. Levels of HIF-1α mRNA, however, were in fact lower in newly infected EBV cells and LCL's in comparison to cytokine-induced proliferating B cells, indicating that HIF-1α protein expression alterations were post-transcriptional and that EBV infection directly results in an HIF-1α increase, rather than resulting from proliferation (Darekar et al., 2012) . Two EBV nuclear antigen proteins, EBNA-3 and EBNA-5, bind directly to PHD-2 and PHD-1, respectively. In glutathione S-transferase pull-down assays of LCLs binding of the EBV nuclear antigens to their appropriate PHD binding partner leads to a concomitant increase in HIF-1α levels within the nucleus, where it can form a heterodimer with HIF-1β and activates the transcription of several target genes.
The second of the two oncogenic herpes viruses, KSHV, causes Kaposi's sarcoma, a cancer highly prevalent in immunosuppressed individuals (Mesri et al., 2010) . The genome of KSHV is relatively large in comparison to other oncogenic viruses (e.g., approximately 170 kilobase pairs for KSHV vs. 8 kilobase pairs for HPV), and contains over 80 open reading frames (ORFs) (Russo et al., 1996) . The 74th ORF of the genome encodes a KSHV viral G-protein coupled receptor (vGPCR) (Bais et al., 1998 (Bais et al., , 2003 Montaner et al., 2001) . Stable transfection of vGPCR into NIH 3T3 mouse fibroblast cells results in activation of MEK and p38 signaling cascades, leading to direct phosphorylation of HIF-1α, and thus subsequent increases in HIF-1 transcriptional activity (Sodhi et al., 2000) . The activation of these two MAPK pathways is diminished in a dosedependent manner by MEK/MAPK and MMK6/p38 pharmacological inhibitors in the vGPCR cells, with a correlative decrease in transcription of HIF-1 target genes. While this study shows that vGPCR, a report on the level of vGPCR mRNA or protein was not included. As well, given the shear number of ORFs in KSHV, studying vGPCR alone may be missing the full complexity of KSHV and its affect on the HIF-1 pathway. In a separate study, vGPCRexpressing cells were found to secrete cytokines that act on neighboring cells in a paracrine fashion to induce HIF-1 and HIF-2 through the Akt, ERK, p38, and inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) pathways, that in turn enhance mTOR-mediated HIF upregulation (Jham et al., 2011) . Blocking the synthesis of HIF-1α using digoxin inhibited the in vivo tumorigenic ability of vGPCR, again indicating that the viral activation of HIF-1 enhances carcinogenesis. Furthermore, the latent nuclear antigen-2 (LANA-2) gene of KSHV, also known as viral interferon regulatory factor 3 (vIRF-3), is implicated in the stabilization of HIF-1α, in addition to its oncogenic role of p53 inhibition (Rivas et al., 2001) . While no differences in mRNA levels were reported, HIF-1α stability was enhanced by LANA-2/vIRF-3 when transfected in SLK endothelial cells . Under normoxic conditions, LANA-2/vIRF-3 binds to the bHLH domain of HIF-1α and inhibits the breakdown of HIF-1α, which seemingly does not have an impact on its dimerization capability, and only further enhances the nuclear localization and transcriptional activity of HIF-1. Although it is now known that LANA-2/vIRF-3 stabilizes HIF-1α leading to its increased transcriptional activity, the exact mechanism of how this occurs remains to be elucidated. Additionally, considering vIRF3 is specifically expressed in host B cells and associated with primary effusion lymphoma (PEL) (Rivas et al., 2001) , its effect on the HIF-1 pathway in endothelial cells may not be congruent in a B cell environment.
The LANA-1 protein of KSHV plays a key role in KSHV's oncogenicity, as it has pRb inhibiting capacity coincident with the ability to obstruct p53 activity (Friborg et al., 1999; Radkov et al., 2000) . Like LANA-2/vIRF-3 and vGPCR, which can enhance HIF-1 activity under normoxic conditions, LANA-1 also has HIF-1 regulating properties. While LANA-2/vIRF-3 increases HIF-1α activity by binding directly to it, LANA-1 further augments HIF-1α stabilization in KSHV-transfected B cells by degrading VHL in the EC 5 S ubiquitin complex (Cai et al., 2006a) . While cotransfection experiments showed HIF-1α to be enhanced by LANA-1, no comment on endogenous levels of HIF-1 was made until a follow up study where the same group found that HIF-1α protein levels are higher in KSHV-positive PEL lines in comparison to KSHV-negative cell lines, and LANA-1 stimulates the nuclear accumulation of HIF-1α (Cai et al., 2007) . RNA interference was used to show that a decrease in LANA-1 was coincident with a decrease in HIF-1α protein levels. The specific regions required for the enhanced nuclear translocation of HIF-1α by LANA-1 were determined to be their oxygen-dependent domain (ODD), and the N-terminus amino acids 46-89, respectively. Lastly, there appears to be a role for KSHV in enhancing the transcription of HIF-1α mRNA in endothelial cells (Carroll et al., 2006) . Clearly, the KSHV virus has adopted numerous distinct mechanisms that activate hypoxic signaling in infected cells, even under normoxic conditions. Interestingly, promoters of key KSHV genes have been found to contain HREs (Haque et al., 2003) , and activation of HIF-1α transcriptional activity by LANA-1 leads to expression of these lytic-reactivating genes (Cai et al., 2006b ). It appears that LANA-1, LANA-2/vIRF-3, and vGPCR enhance HIF1 activity, which in turn induces lytic KSHV genes containing HREs, transitioning the virus from its latent to lytic replication stage.
The human T-cell lymphotropic virus
The human T-cell lymphotropic virus-1 (HTLV-1) is the only retrovirus known to be capable of directly causing cancer (adult T-cell lymphomas or leukemias) in humans (Moore and Chang, 2010) . The HTLV-1 Tax protein is critical for the virus' ability to transform and immortalize T cells (Grassmann et al., 2005) . The Tax protein is responsible for the activation of several oncogenic signaling pathways, including the PI3K/Akt pathway (Peloponese and Jeang, 2006; Jeong et al., 2008) . In a robust study by Tomita and colleagues, HIF-1α protein levels were increased even under normoxic conditions in HTLV-1 positive cell lines in comparison to proliferating T-cell leukemia cell lines not infected with HTLV-1 due to Tax's effect of enhancing PI3K/Akt signaling (Tomita et al., 2007) . Mutants of Tax that were unable to activate PI3K/Akt showed HIF-1 transcriptional activity comparable with untransfected controls. Pharmacological inhibition of the PI3K/Akt pathway showed a dose-dependent decrease in HIF-1 activity seen upon wild-type Tax transfection. Levels of HIF-1α mRNA levels were found to be comparable between both uninfected and HTLVinfected leukemia lines, meaning that the augmentation of HIF-1α protein levels lies solely in post-transcriptional alterations. The proliferation of these cell lines appear directly affected by Taxinduced HIF-1 activity, as knockdown of HIF-1α by way of siRNA significantly decreased the growth rate of HTLV-1 infected leukemia cell lines. This is yet another confirmation that activation of HIF-1α by oncogenic viruses is a key pathway conferring enhanced proliferation, likely by targeting key downstream targets involved in cancer progression.
Downstream activation of genes involved in virally-induced cancer progression by HIF-1

Metabolism
In normal, differentiated cells, glucose is metabolized to pyruvate, followed by oxidative phosphorylation in order to maximize adenosine triphosphate (ATP) as a cellular energy source, however cancer cells exhibit glucose metabolism resembling that of anaerobic cells (Vander Heiden et al., 2009 ). Under aerobic conditions, pyruvate is converted to acetyl-CoA, which subsequently enters the mitochondrial tricarboxylic acid (TCA) cycle, the products of which (NADH, FADH 2 ) donate electrons to the protein complexes of the electron transport chain, generating a proton gradient across the inner mitochondrial membrane. Relying on the presence of molecular oxygen as a final electron acceptor, protons are subsequently transported from the inter-membrane space into the mitochondrial matrix via ATP synthase, which synthesizes ATP from ADP and inorganic phosphate (Schultz and Chan, 2001) . Under hypoxic conditions, however, molecular oxygen is not available as a final electron acceptor, so pyruvate is not converted to acetyl-CoA and subsequent oxidative phosphorylation does not occur. Rather, pyruvate is converted to lactate by the ubiquitous enzyme, lactate dehydrogenase, a process largely governed by activation of HIF-1 and subsequent adaptive gene expression (Semenza, 2000) . It is precisely this hypoxic-like metabolism, with lactate as the major byproduct, that cancer cells perform, even in the presence of adequate oxygen-this phenomenon was first described by famed German physiologist, Otto Warburg, in the 1920s and thus termed the Warburg effect (Warburg et al., 1927; Shaw, 2006) . It is generally thought that the Warburg effect is a requirement for immortalization and malignant transformation of cells, likely due to the reduction in senescence-inducing ROS (e.g., H 2 O 2 , O 2 À ) that arise from a primarily glycolytic mechanism of ATP production, as well as permitting adaptation to the hypoxic environment typical of tumors (Brand and Hermfisse, 1997; Kondoh et al., 2005; Kim and Dang, 2006; Dolado et al., 2007) . Recent evidence has shown that upon infection of certain host target cells, oncoviruses induce molecular changes that account for a Warburg effect (Noch and Khalili, 2012) . In some instances, these metabolic changes are induced following acute infection with an oncovirus (i.e., prior to the formation of a detectable tumor). Therefore, it is likely that the induction of the Warburg effect, either directly or indirectly, confers a proliferative advantage for infected cells and is a necessary step to cancer. Among the genes that are activated by HIF-1 and involve the Warburg effect are those constituting a transition from oxidative phosphorylation to predominately aerobic glycolysis. Metabolic gene targets of HIF-1 have been known for years and it is clear that the enzymes catalyzing glucose metabolism-phosphoglycerate kinase 1 (PGK1), hexokinase 1 and 2 (HK1/2), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphofructokinase (PFK), and the glucose transporters (GLUT-1, GLUT-3)-are upregulated by HIF-1 (Iyer et al., 1998) . Furthermore, key enzymes that contribute to the Warburg effect, such as PDK1 and LDHA, are also HIF-1 targets (Semenza et al., 1994; Lu et al., 2002; Kim and Dang, 2006; Semenza, 2007) .
Due to HIF-1's effect on metabolism, it is not surprising that an increase in lactate production (i.e., Warburg effect) coincides with HIF-1α upregulation by oncoviruses. Early histopathological studies of HPV16 transgenic mice reported a concomitant increase in the mRNA levels of GLUT-1, PGK-1, and HIF-1α in basal keratinocytes during epidermal carcinogenesis (Elson et al., 2000) . Similarly, in EBV-infected LCL cells, EBNA proteins that bind to key PHD proteins (involved in HIF-1α's oxygen dependent degradation) showed a significant increase in metabolic enzymes (approximately 5, 4.5, 3.25, 6.5, and 2 fold increase for PGK1, GAPDH, LDHA, GLUT-1, PDK1, respectively), along with an increase in aerobic glycolysis (i.e., pyruvate and lactate acid production) (Darekar et al., 2012) . HCV viral protein expression has been shown to increase HIF-1α levels in osteosarcoma cells transfected with HCV genes, as well as the transcription of glycolytic enzyme genes and other HIF-1α target genes. These observations coincide with a decrease in oxidative metabolism, forcing ATP production to occur largely via non-oxidative glycolytic metabolism, a HIF-1 controlled 2-2.5-fold transcriptional increase of the glycolytic genes, LDHA and HK1 (Ripoli et al., 2010 ). These observations translate in vivo, where biopsies of HCV-positive hepatocellular carcinomas show a significant increase in HIF-1α and HK1 mRNA over controls. Levels of LDHA mRNA were found to be higher as well, albeit not significantly (Ripoli et al., 2010) . These in vivo results are in agreement with recent studies showing that HCV Core protein transcriptionally upregulates HIF-1α mRNA (Abe et al., 2012) . Other independent studies on the temporal proteome of HCV-infected Huh-7.5 cells found changes consistent with a shift from oxidative metabolism toward aerobic glycolysis, as evidenced by increases in several metabolic HIF-1 targets that are markers of the Warburg Effect upon acute HCV infection (Diamond et al., 2010) . Whether these increases in marker protein levels correlate with a biologically relevant alteration in glucose metabolism by HIF-1 remains to be determined.
In discussions of tumor metabolism, two schools of thought exist. Some contend that HIF-1 induction of the Warburg effect in cancer cells is simply the result of the hypoxic tumor microenvironment (Garber, 2004) . Others argue that the activation of the Warburg effect by HIF-1 is an intrinsic mechanism cancer cells have in order to ensure survival and continued proliferation upon exposure to impending tumor hypoxia, and that without the preceding activation of HIF-1, tumor formation would not be feasible (Garber, 2004) . Central to the latter contention is the fact that many pathways (e.g., the PI3K & MAPK pathways) that are often dysregulated in cancer have an impact on both HIF-1 activity and other pathways involved in cancer progression. As described above, cancers of exogenous origin have (often several) hard-wired mechanisms to increase HIF-1α levels. This supports the notion that HIF-1 is an important factor in permitting initial tumor formation, perhaps by allowing for adaptation to the ensuing hypoxic microenvironment typical of most solid tumors. Some of these HIF-1-inducing oncoviruses cause systemic cancers (e.g., EBV and HTLV-1 induction of B-and T-cell lymphomas, respectively). In such cases where environmental hypoxia in tumor formation is not a characteristic, HIF-1 is likely a key player in the malignant transformation pathway, and not simply a consequence of hypoxia.
Angiogenesis
As with normal tissues, tumors require a constant supply of nutrients that are obtained through the vasculature to ensure cell survival and permit proliferation. To ensure these demands of the rapidly proliferating cells are met, tumors have mechanisms to ensure the formation of blood vessels through angiogenesis (Hanahan and Weinberg, 2011; Carmeliet and Jain, 2011) . New blood vessels in the microenvironment are formed by enhancing pro-angiogenic or by inhibiting anti-angiogenic factors. Perhaps the most studied of the tumor angiogenic factors are those of the vascular endothelial growth factor (VEGF) family, which is also a transcriptional target of HIF-1 (Forsythe et al., 1996) . In fact, we have already discussed several studies containing reports of HIF-1 transcriptional activity based on its ability to activate VEGF-A expression that, in turn, induces angiogenesis via the VEGF receptor-2 (Carmeliet and Jain, 2011) . In this section, we will focus on each oncogenic virus' contribution to angiogenesis via HIF-1.
The oncogenes of HPV have been examined for their ability to induce VEGF expression and angiogenesis via the HIF-1 pathway. The in vitro activation of HIF-1α via E6-induced p53 degradation significantly increases expression of a VEGF reporter gene containing the promoter region of VEGF (which also contains a HIF-1 HRE) (Ravi et al., 2000) . Additionally, in non-small cell lung cancer cells, the overexpression of both HPV16 E6 and E7 oncoproteins is associated with the promotion of angiogenesis both in vitro and in vivo, and is due to enhanced HIF-1α, as well as downstream VEGF mRNA and protein expression (Li et al., 2011) . These studies align with others that have found high-risk HPV oncoproteins capable of inducing pro-angiogenic factors that are transcriptional targets of HIF-1 (Le Buanec et al., 1999; Bequet-Romero and López-Ocejo, 2000; López-Ocejo et al., 2000) . Not surprisingly, pathology studies reveal a similar trend-expression of multiple VEGF isoforms are significantly increased coincidently with the grade of cervical intraepithelial neoplasia (Branca et al., 2006; Baritaki et al., 2007) . These reports agree with the mechanistic findings previously described, wherein both E6 and E7 oncoproteins of high-risk HPV have been found to directly activate HIF-1. Thus, E6 and E7 are likely major factors contributing to VEGF induction, in addition to the development of a hypoxic tumor microenvironment.
Angiogenic factors have also been studied in the context of hepatitis viruses. Both HCV and HBV upregulate VEGF expression through HIF-1. In the case of HCV-positive HCC, several markers of angiogenesis have been found in vivo to be upregulated, notably VEGF-A (Salcedo et al., 2005; Mas et al., 2007) . Moreover, VEGF-A was found to be expressed to significantly higher levels in HCV-HCC than in pre-malignant HCV-induced liver cirrhosis, due to VEGF's importance in cancer development and progression. Experimental in vitro studies have confirmed these findings: VEGF expression follows the increase of HIF-1α that occurs from enhanced HIF-1α synthesis via oxygen-independent pathways (Nasimuzzaman et al., 2007) . Soon after reports of HBV increasing both HIF-1α translation via the MAPK pathway and VEGF angiogenic signaling , it was also revealed that HBx binds to HIF-1α and induces VEGF expression (Moon et al., 2004) . Recent work has implicated the mTOR pathway in VEGF production in HCC by induction of the inflammatory tumor necrosis factor (TNF)-α signaling pathway. A downstream kinase of the TNF-α pathway, the β subunit of the IKKβ, activates mTOR signaling via repression of the TSC1/TSC2 tumor suppressor complex, which in turn leads to enhanced angiogenesis (Lee et al., 2007) . Whether or not the mechanism of IKKβ-induced angiogenesis is HIF-1-mediated VEGF transcriptional upregulation remains to be determined, but it is highly likely to at least be a contributing factor, as enhanced mTOR signaling clearly augments HIF-1 protein synthesis (Majumder et al., 2004; Thomas et al., 2005; Demidenko and Blagosklonny, 2011) , and environmental hypoxia has shown a similar effect on VEGF signaling via mTOR (Humar et al., 2002) . Interestingly, the HBx oncoprotein also activates mTOR signaling and VEGF-A angiogenesis through induction of IKKβ, and activation of key modulators in this pathway is correlated with poor prognosis (Yen et al., 2012) . Again, it remains to be determined if this activation of angiogenic induction requires HIF-1. The exact mechanism of IKKβ upregulation by HBx remains to be elucidated but represents a possible novel pathway of angiogenic signaling (potentially through HIF-1 induction) in cancers arising from viral infection.
Given the promotion of angiogenesis by papillomaviruses and hepatitis viruses through HIF-1, it is not surprising that EBV and KSHV also induce VEGF expression in a similar manner. Several studies of EBV viral proteins that contribute to HIF-1 induction have included analyses of HIF-1-mediated VEGF upregulation. Following early studies that alluded to EBV enhancing VEGF expression (Murono et al., 2001; Krishna et al., 2006; Hui et al., 2002) , each of LMP-1 EBNA-1 (O'Neil et al., 2008) , when studied for their HIF-1 induction capacity, presented increases in VEGF production. Similarly, while trying to determine the molecular underpinnings and the importance of angiogenesis in Kaposi's sarcoma (Cornali et al., 1996; Masood et al., 1997; Bais et al., 1998) , HIF-1α was shown to be activated by KSHV's vGPCR by pathways acting on the mTOR complex that lead to VEGF production. In separate studies, the MAPK and p38 pathways (Sodhi et al., 2000) , as well the paracrine activation of Akt, ERK, p38 and IKKβ on mTOR (Jham et al., 2011 ) result in VEGF induction by this oncogenic virus. In studies using VEGF itself or its promoter (as a proxy of HIF-1 activity), LANA-1 (Cai et al., 2007) and LANA-2/vIRF-3 , through the induction of HIF-1, lead to transcriptional accumulation of VEGF. Lastly, these results are mirrored with regard to human T-cell lymphotropic virus, where HIF-1α levels are increased via activation of the PI3K/Akt pathway, with a concomitant increase in VEGF mRNA (Tomita et al., 2007) .
Invasion and metastasis
It is well documented that metastasis is responsible for up to 90% of cancer deaths, however, researchers are still unraveling the complex mechanisms that contribute to its promotion. Following the discovery that HIF-1 activation is common in cancer (Zhong et al., 1999) , it was promptly shown that it not only contributes to metabolic reprogramming and angiogenesis, but also to metastatic potential by transcriptionally activating several genes that promote invasiveness (Krishnamachary et al., 2003; Semenza, 2003; Fujiwara et al., 2007) . Consequently, several of the key genes involved in amplifying metastatic potential have also been found to be upregulated in both solid and systemic malignancies of viral origin by altering cell adhesion and motility as well as the tumor microenvironment.
Cell adhesion and motility
The downregulation of the epithelial adhesion molecule, E-cadherin, is a common characteristic of carcinomas that promotes invasion (Schipper et al., 1991; Oka et al., 1993; Umbas et al., 1994; Onder et al., 2008; Ma et al., 2010) . E-cadherin repression allows for epithelial-mesenchymal transition (EMT)-an event required for proper embryonic development but also commonly observed with carcinoma metastasis (Chua et al., 2006; Christiansen and Rajasekaran, 2006; Acloque et al., 2008) . Hypoxia can act as a stressor for EMT activation via HIF-1 (Higgins et al., 2007) , because several genes that are E-cadherin repressors and involved in embryonic development, such as Snail and Twist, are HIF-1 targets (reviewed in Yang and Wu, 2008) . A comprehensive study on HCC found a significant correlation of Snail and Twist induction in promoting EMT and metastasis, particularly for HBV-and HCVpositive samples (Yang et al., 2009) . Following this report, in vitro studies indicated that HCV glycoproteins E1 and E2 can contribute to cancer cell migration through the upregulation of Snail and Twist, by virtue of an HIF-1-dependent mechanism (Wilson et al., 2012) . Similarly, the LMP-1 protein of EBV that can enhance HIF-1α levels via mTOR signaling ) also increases Twist (Horikawa et al., 2007) and Snail (Horikawa et al., 2011) expression. Each of these studies found the upregulation of Snail and Twist to inversely correlate with E-cadherin levels and associate with clinical metastases for nasopharyngeal carcinoma (Horikawa et al., 2007 (Horikawa et al., , 2011 . Following reports of HPV16 E6's ability to inhibit E-cadherin levels (Matthews et al., 2003) , similar results to those of hepatitis and Epstein-Barr viruses have been found, where Snail, Twist and/or other E-cadherin repressors that are targets of HIF-1 are upregulated by infection with HPV D'Costa et al., 2012) . Complementary findings have been reported for KSHV as well, where an endothelial-tomesenchymal transition is observed (Gasperini et al., 2012) . Whether or not these results are, in part, mitigated by their respective viral oncoproteins' effect on HIF-1 described previously remains to be determined.
The microenvironment
Research over the past few decades has highlighted the importance of the tumor microenvironment and its associated components in promoting invasion into the bloodstream and subsequent colonization at distant sites. These metastaticpromoting factors may originate from tumor cells themselves or from the very cells of the tumor microenvironment itself (e.g., tumor-associated macrophages) (environmental factors driving cancer cell metastasis reviewed in: Steeg, 2006; Joyce and Pollard, 2009) . One particular environmental factor driving cancer cell metastasis and influenced by HIF-1 is pH. The HIF-1-induced Warburg effect results in a significant increase in lactic acid production, and thus, a requirement for tumor cells to combat a decrease in pH in order to survive. It is not surprising then, that HIF-1 upregulates several pH-regulating membrane transporters, such as a lactate transporter (monocarboxylate transporter 4) and carbonic anhydrase IX and XII (CAIX/XII) (Parks et al., 2013) . While CAIX is often simply used as a hypoxic marker, it also correlates with advanced cancer progression and poor overall survival (Bui et al., 2003; Swinson et al., 2003; Potter and Harris, 2004) . Of particular interest is CAIX's role in counteracting intracellular tumor acidosis (i.e., Warburg effect) by catalyzing the reversible hydration of carbon dioxide, accounting for reports of an observable decrease in extracellular pH, while contributing to tumor growth (Švastová et al., 2004; Chiche et al., 2009) . Recent work has provided evidence of enhanced cancer metastasis under acidic conditions and tumor growth being directed to sites of low pH, indicating that the acidic microenvironment is a key aspect of extracellular matrix remodeling (Estrella et al., 2013) . Furthermore, treatment with NaHCO 3 as pH buffer significantly increases the pH of the tumor microenvironment, while decreasing metastases (Robey et al., 2009; Estrella et al., 2013) . These results may explain additional roles of HIF-1 in enhancing tumor metastases and invasion, via the upregulation of CAIX.
Several tumor viruses have been documented to enhance CAIX expression, often concomitantly with HIF-1 activity increases. The cervical carcinoma cell lines, SiHa and CaSki, which harbor integrated HPV16, have been found to overexpress CAIX . CAIX expression is further augmented (Niccoli et al., 2012) by aggressive HPV16 E6 variants, such that the Asian-American E6 variant (Zehbe et al., 1998) , which is found eight times more often in invasive cervical cancer than prototype E6, relative to noncancer controls (Berumen et al., 2001 ). Thus, CAIX likely represents a key protein in tumor microenvironment hypoxia, and in promoting invasion. Similar results have been reported for the HBx protein of HBV: transient transfection of Hep G2 cells with HBx leads to an increase in CAIX mRNA expression and protein level via HIF-1 (Holotnakova et al., 2010) . Clinical specimens of nasopharyngeal carcinoma, an epithelial cancer for which infection with EBV is a significant risk factor (Lo et al., 1999; zur Hausen et al., 1970) , have been found to exhibit increased expression of HIF-1α and CAIX, and the presence of the latter significantly correlates negatively with progression-free survival (Hui et al., 2002) .
As mentioned, the upregulation of CAIX by HIF-1 is associated with a decrease in extracellular pH (Chiche et al., 2009) , which likely provides an optimal environment of matrix remodeling proteases (such as cathepsins and metalloproteases), as they have been found to have highest activity in an acidic milieu (Buck et al., 1992; Turk et al., 2001; Rofstad et al., 2006) . Matrix metalloprotease-2 (MMP-2) and MMP-9 are two more of the many HIF-1 targets involved in promotion of angiogenesis and invasion through proteolytic cleavage of extracellular matrix components (Semenza, 2003; Choi et al., 2011) . Indeed, either one or both of these MMPs have been found to have increased expression and/or activation of their respective zymogens by oncoviruses including, HPV16 (Coussens et al., 2000; Cardeal et al., 2006) , EBV (Yoshizaki et al., 1998; Horikawa et al., 2000) , HCV (Lichtinghagen et al., 2003; Núñez et al., 2004) , HBV (Kuo et al., 2000; Chung et al., 2004; Liu et al., 2010) , and KSHV (Wang et al., 2004; Qian et al., 2007) . It is worth noting that few studies have reported whether or not activation of these MMPs was directly due to viral genes' activation of HIF-1-this remains a subject of future exploration. However, some studies have documented that the role of the upstream signaling pathways that enhance HIF-1 activity (described earlier) are required for activation of the MMPs under investigation (Chung et al., 2004) and several of the viral oncogenes (such as LMP-1 of EBV) required for target cell transformation and HIF-1, also induce MMP expression (Wakisaka and Pagano, 2003) .
Several additional genes involved in the invasion and metastasis cascade, such as cathepsin D and urokinase plasminogen activator receptor, among others, are targets of HIF-1 (Semenza, 2003) . Whether or not these and other genes involved in metastasis are also activated by HIF-1 in oncoviral cancers has not yet been resolved and remains an attractive area for future work, given the exhaustive evidence for oncoviral HIF-1 activation.
Conclusion and future directions
Following the discovery by Gregg Semenza and colleagues in the mid-1990s that HIF-1 is a key regulator of oxygen homeostasis and adaptation to hypoxia came a plethora of studies elucidating its importance in a variety of health conditions, including cardiovascular disease and cancer. With regard to cancer, HIF-1 is well known to transcriptionally activate genes involved in metabolism, angiogenesis and invasion/metastasis, as it is typically induced within the tumour microenvironment that is notoriously hypoxic. Thus, HIF-1 and its associated mechanisms of upregulation represent an attractive target in the fight against malignancies with detrimental prognoses.
In this review, we have exemplified a unifying theme and the mechanisms therein of viral oncogenes in the activation of HIF-1. Key downstream target genes of HIF-1, including those of metabolism and those that collectively promote proliferation and metastases, have been reviewed in order to accentuate this pathway in viral carcinogenesis. Most of the oncoviruses that have been linked to human cancers have been clearly documented to increase HIF-1 activity, which generally correlates with a poor prognosis. A recently classified oncogenic virus, Merkel cell polyomavirus (MCV) (Feng et al., 2008) , is associated with aggressive carcinomas. Although one study has found inconsistent HIF-1α staining in Merkel cell carcinomas (Fernández-Figueras et al., 2006) , further investigation is required to determine if there is a relationship between MCV and the HIF-1 pathway. While few of the oncoviruses discussed herein have the same method of enhancing HIF-1 levels, the end result is the same: downstream activation of cancer-promoting genes. Although we have highlighted numerous studies that exemplify a link between viral genes and HIF-1, future studies should employ quantitative methods to elucidate molecular mechanisms as present in a natural infection. Appropriate target cell selection for respective viral infections is important to fully understand the context of these viral genes on HIF-1. Ultimately we require a thorough understanding of how intrinsic host cell HIF-1 regulation is affected by viral genomes and their life cycles. However, given the exhaustive evidence for HIF-1 activation by oncoviruses, HIF-1 or the viral genes responsible for its activity represent ideal candidates for targeted therapeutics for cancers of viral etiology.
